These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25399844)

  • 1. Adaptive designs for subpopulation analysis optimizing utility functions.
    Graf AC; Posch M; Koenig F
    Biom J; 2015 Jan; 57(1):76-89. PubMed ID: 25399844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point estimation following two-stage adaptive threshold enrichment clinical trials.
    Kimani PK; Todd S; Renfro LA; Stallard N
    Stat Med; 2018 Sep; 37(22):3179-3196. PubMed ID: 29855066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints.
    Mehta C; Schäfer H; Daniel H; Irle S
    Stat Med; 2014 Nov; 33(26):4515-31. PubMed ID: 25130879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal promising zone designs.
    Hsiao ST; Liu L; Mehta CR
    Biom J; 2019 Sep; 61(5):1175-1186. PubMed ID: 30411405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized adaptive enrichment designs for three-arm trials: learning which subpopulations benefit from different treatments.
    Steingrimsson JA; Betz J; Qian T; Rosenblum M
    Biostatistics; 2021 Apr; 22(2):283-297. PubMed ID: 31420983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of the interim analysis in adaptive enrichment designs.
    Benner L; Kieser M
    J Biopharm Stat; 2018; 28(4):622-632. PubMed ID: 29064745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Confidence regions for treatment effects in subgroups in biomarker stratified designs.
    Wan F; Kunz CU; Jaki TF
    Biom J; 2019 Jan; 61(1):27-39. PubMed ID: 30474226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation after subpopulation selection in adaptive seamless trials.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2015 Aug; 34(18):2581-601. PubMed ID: 25903293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point estimation in adaptive enrichment designs.
    Kunzmann K; Benner L; Kieser M
    Stat Med; 2017 Nov; 36(25):3935-3947. PubMed ID: 28783881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial.
    Ohwada S; Morita S
    Pharm Stat; 2016 Sep; 15(5):420-9. PubMed ID: 27485377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An approach to confirmatory testing of subpopulations in clinical trials.
    Glimm E; Di Scala L
    Biom J; 2015 Sep; 57(5):897-913. PubMed ID: 26033644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-stage adaptive clinical trial design with data-driven subgroup identification at interim analysis.
    Johnston SE; Lipkovich I; Dmitrienko A; Zhao YD
    Pharm Stat; 2022 Sep; 21(5):1090-1108. PubMed ID: 35322520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program.
    Wang SJ
    J Formos Med Assoc; 2008 Dec; 107(12 Suppl):19-27. PubMed ID: 19129042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient recruitment strategies for adaptive enrichment designs with time-to-event endpoints.
    Uozumi R; Yada S; Kawaguchi A
    BMC Med Res Methodol; 2019 Jul; 19(1):159. PubMed ID: 31331277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
    Li W; Chen C; Li X; Beckman RA
    Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized adaptive enrichment designs.
    Ondra T; Jobjörnsson S; Beckman RA; Burman CF; König F; Stallard N; Posch M
    Stat Methods Med Res; 2019 Jul; 28(7):2096-2111. PubMed ID: 29254436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enrichment design with patient population augmentation.
    Yang B; Zhou Y; Zhang L; Cui L
    Contemp Clin Trials; 2015 May; 42():60-7. PubMed ID: 25746817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.